JP2024016207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024016207A5 JP2024016207A5 JP2023191314A JP2023191314A JP2024016207A5 JP 2024016207 A5 JP2024016207 A5 JP 2024016207A5 JP 2023191314 A JP2023191314 A JP 2023191314A JP 2023191314 A JP2023191314 A JP 2023191314A JP 2024016207 A5 JP2024016207 A5 JP 2024016207A5
- Authority
- JP
- Japan
- Prior art keywords
- fab
- liquid suspension
- hvegf
- eye
- raav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006194 liquid suspension Substances 0.000 claims 31
- 241000702421 Dependoparvovirus Species 0.000 claims 14
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 claims 10
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 10
- 206010064930 age-related macular degeneration Diseases 0.000 claims 10
- 230000001105 regulatory effect Effects 0.000 claims 7
- 108091026890 Coding region Proteins 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 210000000234 capsid Anatomy 0.000 claims 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 229960003876 ranibizumab Drugs 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- 102000007469 Actins Human genes 0.000 claims 2
- 108010085238 Actins Proteins 0.000 claims 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 2
- 102100037935 Polyubiquitin-C Human genes 0.000 claims 2
- 108010056354 Ubiquitin C Proteins 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010025421 Macule Diseases 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 208000002352 blister Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 230000008488 polyadenylation Effects 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026018445A JP2026090364A (ja) | 2018-02-20 | 2026-02-06 | 滲出型加齢性黄斑変性の治療のための組成物 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862632775P | 2018-02-20 | 2018-02-20 | |
| US62/632,775 | 2018-02-20 | ||
| US201862663532P | 2018-04-27 | 2018-04-27 | |
| US62/663,532 | 2018-04-27 | ||
| JP2020543914A JP2021516671A (ja) | 2018-02-20 | 2019-02-19 | 滲出型加齢性黄斑変性の治療のための組成物 |
| PCT/US2019/018640 WO2019164854A1 (en) | 2018-02-20 | 2019-02-19 | Compositions for treatment of wet age-related macular degeneration |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543914A Division JP2021516671A (ja) | 2018-02-20 | 2019-02-19 | 滲出型加齢性黄斑変性の治療のための組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026018445A Division JP2026090364A (ja) | 2018-02-20 | 2026-02-06 | 滲出型加齢性黄斑変性の治療のための組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024016207A JP2024016207A (ja) | 2024-02-06 |
| JP2024016207A5 true JP2024016207A5 (enExample) | 2024-08-13 |
Family
ID=67688300
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543914A Pending JP2021516671A (ja) | 2018-02-20 | 2019-02-19 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2023191314A Pending JP2024016207A (ja) | 2018-02-20 | 2023-11-09 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2026018445A Pending JP2026090364A (ja) | 2018-02-20 | 2026-02-06 | 滲出型加齢性黄斑変性の治療のための組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543914A Pending JP2021516671A (ja) | 2018-02-20 | 2019-02-19 | 滲出型加齢性黄斑変性の治療のための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026018445A Pending JP2026090364A (ja) | 2018-02-20 | 2026-02-06 | 滲出型加齢性黄斑変性の治療のための組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12558434B2 (enExample) |
| EP (1) | EP3755804A4 (enExample) |
| JP (3) | JP2021516671A (enExample) |
| KR (1) | KR20210022524A (enExample) |
| AU (2) | AU2019223963A1 (enExample) |
| CA (1) | CA3090293A1 (enExample) |
| IL (1) | IL276777B2 (enExample) |
| MA (1) | MA51916A (enExample) |
| SG (1) | SG11202007252VA (enExample) |
| WO (1) | WO2019164854A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018130284A1 (en) * | 2017-01-12 | 2018-07-19 | Telefonaktiebolaget Lm Ericsson (Publ) | Anomaly detection of media event sequences |
| CA3076905A1 (en) * | 2017-09-27 | 2019-04-04 | The Johns Hopkins University | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| CA3086045A1 (en) | 2017-12-19 | 2019-06-27 | Akouos, Inc. | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| US11360969B2 (en) | 2019-03-20 | 2022-06-14 | Promethium, Inc. | Natural language based processing of data stored across heterogeneous data sources |
| WO2021046245A1 (en) * | 2019-09-04 | 2021-03-11 | University Of Massachusetts | Adeno-associated virus vector platform for delivery of kh902 (conbercept) and uses thereof |
| BR112022017182A2 (pt) * | 2020-02-28 | 2022-11-08 | Univ Pennsylvania | Tratamento de bestrofinopatias autossômicas recessivas e métodos para avaliação das mesmas |
| EP4138918B1 (en) * | 2020-04-24 | 2026-07-22 | Siemens Healthcare Diagnostics Inc. | Calibration and quality control reagents for use with immunoassays for antibodies |
| WO2021255589A1 (en) * | 2020-06-16 | 2021-12-23 | Intas Pharmaceuticals Ltd. | An anti-vegf scfab adeno-associated virus (aav) vector and uses thereof |
| WO2021255590A1 (en) * | 2020-06-16 | 2021-12-23 | Intas Pharmaceuticals Ltd. | An anti-vegf scfv adeno-associated virus (aav) vector and uses thereof |
| KR20230088630A (ko) | 2020-10-16 | 2023-06-20 | 자이로스코프 테라퓨틱스 리미티드 | 항-vegf 엔티티 및 음성 보체 조절인자를 코딩하는 핵산 및 연령-관련 황반 변성의 치료를 위한 그의 용도 |
| IL303317A (en) * | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| MX2023008826A (es) | 2021-02-01 | 2023-09-15 | Regenxbio Inc | Terapia génica para lipofuscinosis neuronal ceroidea. |
| WO2023014892A1 (en) * | 2021-08-04 | 2023-02-09 | Alpine Biotherapeutics Corporation | Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders |
| CN114181972A (zh) * | 2021-11-23 | 2022-03-15 | 上海本导基因技术有限公司 | 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体 |
| KR102789747B1 (ko) * | 2021-12-29 | 2025-04-03 | 한국과학기술원 | Prox1 단백질에 중화 활성을 갖는 결합 분자 |
| AR128422A1 (es) * | 2022-02-02 | 2024-05-08 | Akouos Inc | Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular |
| WO2024238859A1 (en) * | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Vectorized c5 inhibitor agents and administration thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT73101A (en) | 1993-02-12 | 1996-06-28 | Harvard College | Method for regulating transcription of targeted genes and other biological events |
| ATE544776T1 (de) | 1994-12-29 | 2012-02-15 | Massachusetts Inst Technology | Chimäre dna-bindeproteine |
| KR19990022651A (ko) | 1995-06-07 | 1999-03-25 | 데이비드 엘. 버스테인 | 생물학적 사건에 대한 라파마이신 기재 조절방법 |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| JP2003524368A (ja) | 1997-08-26 | 2003-08-19 | アリアド ジーン セラピューティクス インコーポレイテッド | ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白 |
| IL134643A0 (en) | 1997-08-27 | 2001-04-30 | Ariad Gene Therapeutics Inc | Chimeric transcriptional activators and compositions and uses related thereto |
| WO1999036553A2 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
| JP2002503667A (ja) | 1998-02-13 | 2002-02-05 | プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 新規な二量体化剤、その製造および使用 |
| US6596535B1 (en) | 1999-08-09 | 2003-07-22 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for the preparation and use |
| US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
| CA2388432A1 (en) | 1999-10-21 | 2001-04-26 | Monsanto Company | Post-translational modification of recombinant proteins produced in plants |
| GB2362884A (en) | 2000-05-30 | 2001-12-05 | Isis Innovation | Extended duration of airway gene therapy |
| US20020068694A1 (en) | 2000-07-26 | 2002-06-06 | Jeltsch Markku Michael | Glycosylated VEGF-B and method for increasing the amount of soluble VEGF-B |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| MXPA04007583A (es) | 2002-02-11 | 2005-04-25 | Genentech Inc | Variantes de anticuerpo con tasas mas rapidas de asociacion a antigeno. |
| US20040208847A1 (en) | 2003-03-28 | 2004-10-21 | Fabienne Rolling | Method and vectors for selectively transducing retinal pigment epithelium cells |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| DE23193606T1 (de) | 2005-04-07 | 2024-02-15 | The Trustees Of The University Of Pennsylvania | Verfahren zur erhöhung der funktion eines aav-vektors |
| JP4495210B2 (ja) | 2005-06-09 | 2010-06-30 | パナソニック株式会社 | 振幅誤差補償装置及び直交度誤差補償装置 |
| HUE024877T2 (en) | 2007-10-30 | 2016-02-29 | Genentech Inc | Antibody purification by cation exchange chromatography |
| TWI468417B (zh) | 2007-11-30 | 2015-01-11 | Genentech Inc | 抗－ｖｅｇｆ抗體 |
| KR101010352B1 (ko) | 2008-05-30 | 2011-01-25 | 삼성중공업 주식회사 | 전력 제어 장치 및 방법 |
| US9221902B2 (en) | 2008-11-07 | 2015-12-29 | Fabrus, Inc. | Combinatorial antibody libraries and uses thereof |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| RU2567639C2 (ru) * | 2009-06-17 | 2015-11-10 | АббВай Биотерапеутикс Инк., | Антитела против vegf и их применения |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| US10738326B2 (en) | 2010-10-27 | 2020-08-11 | Jichi Medical University | Adeno-associated virus vector for gene transfer to nervous system cells |
| CA2826273C (en) | 2011-02-10 | 2021-11-02 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| DK3693025T3 (da) | 2011-04-22 | 2022-01-10 | Univ California | Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf |
| EP2559443A1 (en) | 2011-08-16 | 2013-02-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject |
| EP3795581A3 (en) | 2011-08-24 | 2021-06-09 | The Board of Trustees of the Leland Stanford Junior University | New avv capsid proteins for nucleic acid transfer |
| US20130090375A1 (en) | 2011-10-06 | 2013-04-11 | Cornell University | Virus-mediated delivery of bevacizumab for therapeutic applications |
| EP3470523A1 (en) | 2012-05-09 | 2019-04-17 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| TWI698240B (zh) * | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| AU2013342275B2 (en) | 2012-11-08 | 2017-11-09 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| WO2014124282A1 (en) | 2013-02-08 | 2014-08-14 | The Trustees Of The University Of Pennsylvania | Enhanced aav-mediated gene transfer for retinal therapies |
| EP2970946A4 (en) | 2013-03-13 | 2016-09-07 | Philadelphia Children Hospital | ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF |
| BR112015021036A2 (pt) | 2013-03-15 | 2017-10-10 | Univ Pennsylvania | composições e métodos para tratar mps1 |
| EP3564379A1 (en) | 2013-09-13 | 2019-11-06 | California Institute of Technology | Selective recovery |
| HUE052676T2 (hu) | 2013-10-11 | 2021-05-28 | Massachusetts Eye & Ear Infirmary | Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik |
| RS61993B1 (sr) | 2013-12-03 | 2021-07-30 | Hookipa Biotech Gmbh | Cmv vakcine |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| US10746742B2 (en) | 2014-04-25 | 2020-08-18 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| US11555059B2 (en) | 2014-04-25 | 2023-01-17 | The Trustees Of The University Of Pennsylvania | LDLR variants and their use in compositions for reducing cholesterol levels |
| CR20160519A (es) | 2014-05-13 | 2017-01-27 | The Trustees Of The Univ Of Pennysylvania | Composiciones que comprenden avv que expresa constructos de anticuerpos duales y sus usos |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| US10064752B2 (en) | 2014-09-11 | 2018-09-04 | Orbit Biomedical Limited | Motorized suprachoroidal injection of therapeutic agent |
| CA2977355A1 (en) | 2015-02-20 | 2016-08-25 | University Of Iowa Research Foundation | Methods and compositions for treating genetic eye diseases |
| WO2016200543A2 (en) | 2015-05-13 | 2016-12-15 | The Trustees Of The University Of Pennsylvania | Aav-mediated expression of anti-inluenza antibodies and methods of use thereof |
| EP3344294A4 (en) | 2015-08-31 | 2019-03-20 | The Trustees Of The University Of Pennsylvania | CHIMERIC AAV ANTI-VEGF FOR THE TREATMENT OF CANCER IN DOGS |
| GB201519086D0 (en) | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
| CN108778330A (zh) | 2016-01-08 | 2018-11-09 | 科尼尔赛德生物医学公司 | 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置 |
| JP2019515027A (ja) | 2016-04-15 | 2019-06-06 | レジェンクスバイオ インコーポレーテッド | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| IL262207B2 (en) * | 2016-04-15 | 2026-01-01 | Univ Pennsylvania | Preparations for the treatment of wet age-related macular degeneration |
| CA3076905A1 (en) | 2017-09-27 | 2019-04-04 | The Johns Hopkins University | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| EP4667578A3 (en) | 2019-04-03 | 2026-04-01 | REGENXBIO Inc. | Gene therapy for eye pathologies |
-
2019
- 2019-02-18 US US16/971,215 patent/US12558434B2/en active Active
- 2019-02-19 CA CA3090293A patent/CA3090293A1/en active Pending
- 2019-02-19 IL IL276777A patent/IL276777B2/en unknown
- 2019-02-19 AU AU2019223963A patent/AU2019223963A1/en not_active Abandoned
- 2019-02-19 SG SG11202007252VA patent/SG11202007252VA/en unknown
- 2019-02-19 JP JP2020543914A patent/JP2021516671A/ja active Pending
- 2019-02-19 MA MA051916A patent/MA51916A/fr unknown
- 2019-02-19 WO PCT/US2019/018640 patent/WO2019164854A1/en not_active Ceased
- 2019-02-19 KR KR1020207026455A patent/KR20210022524A/ko not_active Ceased
- 2019-02-19 EP EP19757101.1A patent/EP3755804A4/en active Pending
-
2023
- 2023-11-09 JP JP2023191314A patent/JP2024016207A/ja active Pending
-
2025
- 2025-06-25 AU AU2025204780A patent/AU2025204780A1/en active Pending
-
2026
- 2026-02-06 JP JP2026018445A patent/JP2026090364A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022153418A5 (enExample) | ||
| JP2021516671A5 (enExample) | ||
| KR102616820B1 (ko) | 향상된 유전자 발현을 위한 조성물 및 방법 | |
| JP2025000642A5 (enExample) | ||
| JP2019518427A5 (enExample) | ||
| FI3717636T3 (fi) | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä | |
| JP2022552262A5 (enExample) | ||
| JP2020510424A5 (enExample) | ||
| US20200297869A1 (en) | Sequential intravitreal administration of aav gene therapy to contralateral eyes | |
| JP2022522776A5 (enExample) | ||
| RU2018142768A (ru) | Варианты капсидов аденоассоциированного вируса и способы их применения | |
| JP2022545967A5 (enExample) | ||
| JP2023545424A5 (enExample) | ||
| JP2011512417A (ja) | 血管形成の阻害 | |
| EP4549459A1 (en) | Aav drug for treating angiogenesis-related fundus diseases | |
| US20130090375A1 (en) | Virus-mediated delivery of bevacizumab for therapeutic applications | |
| KR20240150793A (ko) | Vegf 결합 분자 및 이의 의약적 용도 | |
| KR20240116840A (ko) | 변형된 aav 캡시드 단백질 및 이의 용도 | |
| JP2023545229A5 (enExample) | ||
| CN117242183A (zh) | 用于治疗与血管生成相关的眼部疾病的组合物和方法 | |
| AU2024261900A1 (en) | Nucleic acid encoding anti-vegf protein, polynucleotide expression cassette and recombinant adeno-associated virus | |
| JP2023547832A5 (enExample) | ||
| US20240279324A1 (en) | Multispecific antagonists | |
| CN117736274A (zh) | 一种腺相关病毒衣壳蛋白及其用途 | |
| KR20240107201A (ko) | 항원-결합 분자 및 이의 용도 |